Carotenoid Prebiotic Composition for Microbiome Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current prebiotic compositions are inadequate in effectively supporting the growth of health-beneficial bacteria in the gut and skin microbiome, leading to imbalances that contribute to various diseases such as obesity, neurodegenerative disorders, and inflammatory conditions.
Innovation Solution
Administration of carotenoids, particularly lycopene, which acts as a prebiotic to increase the population of beneficial Bifidobacterium and decrease pathology-associated bacteria like Bacteroidetes, Prevotella, and Desulfovibrio, thereby promoting a healthy gut and skin microbiome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional prebiotic compositions are used, then some beneficial effects on gut microflora are achieved, but they are inadequate in effectively supporting the growth of health-beneficial bacteria
Solution Approach 1:
The patent combines multiple prebiotic substances (inulin, oligofructose, galacto-oligosaccharides, lactulose, and breast milk oligosaccharides) in specific proportions to create a composite prebiotic composition that synergistically supports the growth of beneficial bacteria, particularly Bifidobacterium species, more effectively than single prebiotic substances alone
2Productivity
If prebiotics are administered to influence gut environment, then health benefits are achieved, but the microbiome balance is not sufficiently improved
Solution Approach 1:
The patent optimizes the concentration ratios of different prebiotic substances in the composition, specifically adjusting the proportions of inulin, oligofructose, galacto-oligosaccharides, lactulose, and breast milk oligosaccharides to create optimal conditions for selective growth of beneficial bacteria while suppressing pathogenic bacteria, thereby improving both growth rate and compositional stability of the microbiome
Data Source
AI summary
The present disclosure relates to administration of carotenoids to provide a prebiotic effect for modification of gut microbiome, thereby increasing counts of Bifidobacterium adolescentis and/or decreasing counts of pathology-associated bacteria from phylum Bacteroidetes, and its particular genus Prevotella, and also genera from other phyla such as Desulfovibrio and Dialister, and resulting in improved systemic effects.